Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, has announced plans to launch Ropivacaine Hydrochloride Injection USP in November 2025. The new product, available in three strengths, expands Glenmark’s injectable portfolio and offers an affordable alternative to existing therapies in the market.
Product Details
Glenmark’s Ropivacaine Hydrochloride Injection USP will be supplied in the following single-dose vial strengths:
| Strength | Volume |
| 40 mg | 20 mL |
| 150 mg | 30 mL |
| 200 mg | 20 mL |
The injection is bioequivalent and therapeutically equivalent to Naropin® Injection, produced by Fresenius Kabi USA, LLC. Naropin® reported annual sales of $20.90 million for the 12 months ending August 2025, highlighting a significant market opportunity for Glenmark.
Market Impact
The launch positions Glenmark to compete directly with Naropin®, providing cost-effective alternatives to healthcare providers and patients. This aligns with the company’s strategy to expand its injectable portfolio and strengthen its presence in the North American pharmaceutical market.
Company Statement
Marc Kikuchi, President & Business Head, North America, stated:
“We are pleased to announce the launch of Ropivacaine Hydrochloride Injection USP. This launch represents another important addition to Glenmark’s expanding injectable portfolio and reinforces our dedication to bring quality and affordable alternatives to market for patients in need.”
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company with operations across Branded, Generics, and OTC segments, focusing on respiratory, dermatology, and oncology. With 11 manufacturing facilities spanning four continents and a presence in over 80 countries, Glenmark has established a strong international footprint.
The company is also committed to sustainability, achieving approval from the Science Based Target initiative (SBTi) for its GHG emission reduction targets, becoming only the second pharmaceutical company in India to receive this recognition.
Summary
The upcoming launch of Ropivacaine Hydrochloride Injection USP in November 2025 enhances Glenmark’s injectable portfolio, offering a bioequivalent and affordable alternative to Naropin®. This move strengthens Glenmark’s competitive positioning in the pharmaceutical market while reinforcing its commitment to quality, accessibility, and sustainable growth.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.